RLAY - Relay Therapeutics GAAP EPS of -$0.57 beats by $0.05 revenue of $0.42M
Relay Therapeutics press release (NASDAQ:RLAY): Q1 GAAP EPS of -$0.57 beats by $0.05. Revenue of $0.42M (-55.8% Y/Y). As of March 31, 2022, cash, cash equivalents and investments totaled approximately $898 million compared to $958 million as of December 31, 2021.
For further details see:
Relay Therapeutics GAAP EPS of -$0.57 beats by $0.05, revenue of $0.42M